Mnemonic coding system for clinical data entry into laboratory computers: its effect on quality and efficiency.

Bailey, Ian R; Page, Katherine; Jones, R G; Payne, Richard E.; Little, A J

doi:10.1136/jcp.44.12.1018

Cited by 3 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a retrospective study, only 15 of 16,223 patients (0.09%) who had undergone vascular procedures were found to have CES 4. In three autopsy studies, incidence of spontaneous CES was found to be 0.79%–3.4% which was most frequently observed in elderly patients 7…”

Section: Epidemiologymentioning

confidence: 99%

“…Although there has been significant variability among studies, the incidence of clinically evident CES has been reported to be 0.09%–2.9% 4–6. In autopsy series, CES was found at a frequency of 0.31%–2.4% 7,8. However CES frequency was significantly higher (12%–77%) in autopsy studies performed on selected populations ,such as elderly patients who had died after aortic surgery or aortography 9,10…”

Section: Epidemiologymentioning

confidence: 99%

See 1 more Smart Citation

<p>Cholesterol-embolization syndrome: current perspectives</p>

Özkök¹

2019

VHRM

View full text Add to dashboard Cite

Cholesterol-embolization syndrome (CES) is a multisystemic disease with various clinical manifestations. CES is caused by embolization of cholesterol crystals (CCs) from atherosclerotic plaques located in the major arteries, and is induced mostly iatrogenically by interventional and surgical procedures; however, it may also occur spontaneously. Embolized CCs lead to both ischemic and inflammatory damage to the target organ. Therefore, anti-inflammatory agents, such as corticosteroids and cyclophosphamide, have been investigated as treatment for CES in several studies, with conflicting results. Recent research has revealed that CES is actually a kind of autoinflammatory disease in which inflammasome pathways, such as NLRP3 and IL1, are induced by CCs. These recent findings may have clinical implications such that colchicine and IL1 inhibitors, namely canakinumab, may be beneficial in the early stages of CES.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Section: Epidemiologymentioning

confidence: 99%

<p>Cholesterol-embolization syndrome: current perspectives</p>

Özkök¹

2019

VHRM

View full text Add to dashboard Cite

show abstract

“…Spontaneous plaque ruptures are predominantly observed in patients over 60 years old, with an incidence of 0.79%-3.4%. 23 Smoking is another risk factor for CC embolism syndrome. Various chemical components, such as nicotine, present in tobacco smoke directly cause endothelial damage and enhance inflammatory responses in the vascular wall due to the oxidant and proinflammatory properties of nicotine molecules.…”

Section: Risk Factors For CC Embolismmentioning

confidence: 99%

“…Age is another important risk factor in CC embolism syndrome. Spontaneous plaque ruptures are predominantly observed in patients over 60 years old, with an incidence of 0.79%–3.4% 23 …”

Section: Risk Factors For CC Embolismmentioning

confidence: 99%

Pathophysiology and targeted treatment of cholesterol crystal embolism and the related thrombotic angiopathy

Shi,

Mammadova‐Bach,

et al. 2023

The FASEB Journal

View full text Add to dashboard Cite

Cholesterol crystal (CC) embolism is a complication of advanced atherosclerotic plaques located in the major arteries. This pathological condition is primarily induced by interventional and surgical procedures or occurs spontaneously. CC can induce a wide range of tissue injuries including CC embolism syndrome, a spontaneous or intervention‐induced complication of advanced atherosclerosis, while treatment of CC embolism has remained empiric. Vascular occlusions caused by CC embolism may exceed the ischemia tolerance of many tissues, particularly when small arteries are affected. The main approach to CC embolism is primary prophylaxis in patients at risk by stabilizing atherosclerotic plaques and avoiding unnecessary catheter interventions. During CC embolism, the use of platelet inhibitors to avoid abnormal activation and aggregation and anticoagulants may reduce the risk of vascular occlusions and tissue ischemia. This probably explains the relatively low prevalence of clinical manifestations of CC embolism, which are frequently found in autopsy studies. In this review, we summarized the current knowledge on the pathophysiology of CC embolism syndrome deriving from clinical observations and experimental mouse models. Furthermore, we described the risk factors of CC embolism in humans as well as the experimental studies based on empiric treatments. We also discuss potential therapeutic interventions based on recent experimental data and emerging drug options evolving from other research domains. Given the substantial unmet medical need to improve the outcomes of CC embolism, the identification of effective treatment strategies is urgently needed.

show abstract

Review

1996

CCLM

View full text Add to dashboard Cite

Computer-assisted processing of medical laboratory data started in the sixties. The earliest systems, which arose in English-and German-speaking laboratories, pointed the way for the development of laboratory data processing. The significance and evolution of the fundamental components of a laboratory information system, such as the placing of the request to the laboratory, identification of patients and samples, recording of data, quality control, plausibility control and results, are presented.The subject is given a wider perspective by the inclusion of a comprehensive (chronological) literature index.

show abstract

Mnemonic coding system for clinical data entry into laboratory computers: its effect on quality and efficiency.

Cited by 3 publications

References 4 publications

<p>Cholesterol-embolization syndrome: current perspectives</p>

<p>Cholesterol-embolization syndrome: current perspectives</p>

Pathophysiology and targeted treatment of cholesterol crystal embolism and the related thrombotic angiopathy

Review

Contact Info

Product

Resources

About